Research News
A clinical trial for an investigational eye drop to treat wet age-related macular degeneration is seeking eligible participants for enrollment.
BrightFocus Foundation Macular Degeneration Research grant recipient Maximilian Pfau, MD, aims to bridge this gap in available testing for AMD and detect the condition as early as possible. Learn more about his Macular Degeneration Research-funded project.
Increased eye inflammation with age may contribute to macular degeneration and present differently between sexes, suggests a new BrightFocus-funded study.
A new BrightFocus study is revolutionizing our understanding of the eye through research on choroidal blood flow, potentially unlocking future treatments for macular degeneration.
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
A potential drug rooted in initial grant funding from BrightFocus Foundation to Dr. Ilyas Washington gives hope to those suffering from Stargardt disease, a genetic form of macular degeneration.
Researchers have successfully demonstrated that hagfish slime proteins can accurately replicate membranes in the human eye.
The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Taking a unique approach to better diagnose and treat one of the world’s leading causes of blindness, a researcher from the University of Canberra in Australia has received a $500,000 boost for his three-year project, thanks to a grant from BrightFocus Foundation’s Macular Degeneration Research program.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
